免疫療法に関連する心血管毒性:メカニズムから管理まで
Lifeng Xiao1, Weitong Liu2, Yanchen Ji3
1Department of Emergency, Cancer Hospital of Shantou University Medical College, Shantou, China.
Frontiers in pharmacology
|February 20, 2026
まとめ
チェックポイント阻害剤やCAR-T細胞などのがん免疫療法は,心臓の問題を引き起こす可能性があります. このレビューでは,心血管への毒性,メカニズム,およびより良い患者の結果のための管理戦略について説明します.
科学分野:
- 心臓腫瘍学 (Cardio-oncology) について
- 免疫療法による有害事象
背景:
- 癌の免疫療法は,腫瘍学的治療法を変えました.
- 心血管の毒性は,これらの治療法で重要な懸念事項です.
研究 の 目的:
- 癌免疫療法に関連した心血管毒性をレビューする.
- メカニズム,リスクの階層化,モニタリング,マネジメントを調査する.
- 心臓腫瘍学における将来の方向性を議論する.
主な方法:
- 循環器系の有害事象に関する包括的な文献レビュー.
- 病理生理学的メカニズムの分析.
- 現在の管理・監視戦略の評価.
主要な成果:
- 免疫療法に関連した心血管毒性には,心筋梗塞,心周病,心律不全,心不全が含まれます.
- そのメカニズムは,T細胞の交叉反応性とサイトカイン放出症候群を含む.
- 効果的なマネジメントには,リスクの階層化,モニタリング,そして多学科的なケアが必要です.
結論:
- 積極的な心臓腫瘍学的アプローチは不可欠です.
- 心血管疾患のリスクを軽減することは,安全な免疫療法の使用に不可欠です.
- 将来の研究は,新しい目標と高度なモニタリングに焦点を当てるべきです.
関連する概念動画
Myocarditis III: Medical Management
238
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
238
Tumor Immunotherapy
2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Myocarditis IV: Nursing Management
277
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
277
Pericarditis III: Medical Management
404
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
404
Cardiomyopathy V: Interprofessional Care
501
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
501
Heart Failure Drugs: Inotropic Agents
1.6K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.6K


